Written Question · S2W-31920 · Session 2
When it expects a decision to be made on the approval of Lucentis for the treatment of age-related macular degeneration.
The question
To ask the Scottish Executive when it expects a decision to be made on the approval of Lucentis for the treatment of age-related macular degeneration.
The answer
Lucentis® (ranibizumab) was approvedon 22 January 2007 by the European Medicines Evaluation Agency (EMEA). the Scottish Medicines Consortium have this therapy on their work programme and a recommendationis anticipated from them in the next few months.
In the Official Report
No contribution in the Official Report cites S2W-31920 by reference.